Gossamer Bio, Inc. - GOSS
About Gravity Analytica
Recent News
- 01.30.2026 - Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
- 01.30.2026 - Seralutinib demonstrated in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension
- 01.29.2026 - Seralutinib decreases endotrophin (PRO-C6) production, a mediator of fibrosis and inflammation, in an in vitro model of pulmonary fibrosis
- 01.29.2026 - Trial in progress: SERANATA, a phase 3 randomized, placebo-controlled trial to evaluate inhaled seralutinib for treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- 01.29.2026 - Seralutinib targets fibrotic pathways in IPF: Evidence from single-cell transcriptomics
- 12.05.2025 - Mapping the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease
- 12.05.2025 - A Mixed Methods Analysis of Undertreatment and Delays in Therapy Escalation in Pulmonary Arterial Hypertension: Insights From a Real-world Patient Journey Study in the US
- 11.13.2025 - Mapping the Diagnostic Journey of Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD): A Retrospective U.S. Claims Analysis
- 11.13.2025 - Seralutinib Preserved Lung Function and Displayed Broad Anti-Fibrotic Activity in Models of Pulmonary Fibrosis
Recent Filings
- 01.28.2026 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
- 01.21.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
- 11.05.2025 - 8-K Current report
- 11.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]